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Executive Summary 
The inherent risks of substance use are significantly increased for drugs procured on the illegal 
market, where there is no quality control and drug contents are unpredictable. Drug adulteration — 
the presence of substances in addition to the expected one — increases the risk of accidental 
poisoning and other harms because people who use drugs do not know what substances they are 
using or how much. 
This report provides a snapshot of the contents of drugs on the unregulated market in Canada, with 
the view to raising awareness among stakeholders, including people who use drugs, direct service 
providers and policy makers, that adulteration is extensive and pervasive, and contributes 
significantly to drug-related harms.  
The report summarizes data from three primary sources:  
• Health Canada’s Drug Analysis Service (DAS), which identifies substances contained in samples 
seized by law enforcement; 
• A drug content monitoring study consisting of surveys of people who use drugs and concurrent 
urine screening (urinalysis) results; and 
• Drug checking service providers who are members of Canada’s national Drug Checking Working 
Group. 
Across these data sources, the trends described below emerged. 
Drugs on the Illegal Market Tend to Contain Unexpected Substances 
In samples analyzed by DAS, many co-occurring substances were present: 
• Among opioid-containing samples, one in eight (13%) contained another psychoactive 
substance, increasing to over two-thirds (69%) when including cutting agents; 
• Among methamphetamine-containing samples, more than one in ten (11%) contained another 
psychoactive substance, increasing to almost half (46%) when including cutting agents; and  
• Among cocaine-containing samples, one in 20 (5%) contained another psychoactive substance, 
increasing to almost a third (29%) when including cutting agents. 
Drug checking and drug content monitoring data confirmed that this co-occurrence is not always 
expected or wanted. 
Fentanyl and Its Analogues Are Common in the Illegal Drug Supply 
Nationally, fentanyl or analogues were present in nearly two-thirds (62%) of opioid-containing 
samples and up to 3% of stimulant-containing samples (DAS data). In British Columbia fentanyl or 
analogues were present in 91% of opioid-containing and up to 10% of stimulant-containing samples. 
Fentanyl and Its Analogues Are Not Always Used Intentionally or Knowingly  
Among survey respondents with fentanyl-positive urine screens (59% of respondents in B.C., 10% in 
Montreal), over one-third (36%) in B.C. and over 90% in Montreal did not report consuming fentanyl, 
suggesting they were unintentionally or unknowingly exposed. 
Drug checking data from Ontario and B.C. indicated fentanyl in samples expected to be heroin or 
stimulants, and in pills resembling Percocet™ (oxycodone and paracetamol) and Xanax™ (alprazolam). 
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Presence of fentanyl in non-opioid drugs is particularly concerning as accidental poisoning is more 
likely among people who are not expecting opioids and might be opioid-naïve or have low tolerance. 
Drug checking also detected carfentanil and other fentanyl analogues in samples expected to be 
fentanyl. This is of concern because some analogues are more toxic than fentanyl. 
Other Unexpected Psychoactive Substances Can Also Contribute to Health Risks  
Increasingly, reports also point to the presence of other substances associated with health risks in 
the unregulated drug supply. These substances include: 
• Novel synthetic opioids (particularly U-47700 and other compounds in the U-series); 
• Benzodiazepines (particularly etizolam, flualprazolam and flubromazolam); and 
• Synthetic cannabinoids (particularly AMB-FUBINACA). 
These substances are of concern because they can alter overdose symptoms and respond differently 
to overdose interventions (e.g., benzodiazepines do not respond to naloxone), and they are not 
always detected by drug checking (e.g., immunoassay test strips).  
There Is Significant Regional Variation in the Findings 
In western Canada: 
• There is more fentanyl than in samples seized in the east. 
- 91% of opioid-containing samples in B.C. included fentanyl or an analogue, compared to 69% 
nationwide, 55% in Ontario and 14% in the province of Quebec (DAS data). 
- In B.C., fentanyl was the third-most reported drug to have been recently used, whereas it was 
not in the top five in Montreal. 
• The presence of fentanyl in stimulants might be greater than in the east. 
- In B.C., fentanyl and analogues were present in 10% of methamphetamine-containing samples 
and 7% of cocaine-containing samples, compared to 3% nationally and less than 1% in 
Quebec. 
• Opioids are more often contaminated with other substances than in the east. 
- 91% of opioid-containing samples in B.C. contained other, non-opioid substances (primarily 
cutting agents), compared to 25% in the province of Quebec. 
In eastern Canada:  
• Even though there appears to be more stimulant-related harm occurring in western Canada, 
stimulants are more widely available in eastern Canada than opioids. 
- The three drugs reported as most frequently used in Montreal among clients accessing harm 
reduction services were stimulants: crack, cocaine and “speed.” 
- The highest number of methamphetamine-containing samples analyzed by DAS were seized 
in Quebec (38% of all methamphetamine-containing samples nationwide). 
• Stimulants are more often contaminated with other substances than in the west. 
- 95% of methamphetamine-containing samples in Quebec contained other substances 
(primarily cutting agents), compared to less than 14% in the Prairies and B.C. (DAS data). 
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- However, in the west stimulant-containing samples were more likely to include fentanyl and 
its analogues, which might be why more harms associated with methamphetamine are 
reported in western Canada. 
Implications 
Based on the results presented in this report, the following next steps should be considered. 
Establish a Canadian drugs observatory service to: 
• Monitor drug contents and track adverse health effects to identify concerning trends;  
• Improve harmonization of data collection to allow comparison across regions in Canada;   
• Rapidly disseminate drug-related health alerts and response options; and 
• Raise public awareness of the link between drug unpredictability and health harms. 
Further develop treatment and harm reduction services, including support for: 
• Education and dissemination of information among people who use drugs to ensure they are 
aware of contaminants, harm reduction options and substance poisoning interventions;  
• Sustainability and scale up of easily accessible harm reduction services (e.g., drug checking and 
supervised consumption services) to increase national coverage;  
• Continued naloxone availability and overdose response training, including updated protocols to 
respond to inadvertent polysubstance use; and 
• Increased investment in a range of treatment options to ensure that people who use drugs and 
those with a substance use disorder receive the needed services. 
Decrease drug-related harms by advancing approaches that increase the predictability of drug 
contents. Such approaches include “safer supply” programs such as injectable opioid agonist 
treatment (Fairbairn et al., 2019) and low-barrier opioid distribution programs (Tyndall, 2018). As the 
evidence around these approaches is limited, next steps could include: 
• Synthesizing the available evidence to identify research gaps and formulating recommendations 
to address them; 
• Exploring and evaluating various models of delivery for such interventions to produce evidence-
informed recommendations for program development, scale-up and sustainability; 
• Evaluating context variables to assess what works best, for whom and why, as well as evaluating 
the long-term safety and efficacy of these interventions; 
• Investigating the feasibility of applying a similar approach to non-opioid drugs, in light of our 
finding that contamination is widespread across the drug supply and that there is increased 
methamphetamine use across the country. Proposals for stimulant substitution or distribution 
programs have been put forward (Canadian Association of People Who Use Drugs, 2019; 
Fleming, Barker, Ivsins, Vakharia, & McNeil, 2020), and could be piloted and evaluated; and 
• Analyzing the regulatory and policy barriers that need to be addressed, and employing the policy 
levers and facilitators that are available, to enable the development, scale-up and stability of 
successful interventions beyond the pilot phase. 
It will also be important to monitor and assess whether large scale social changes resulting from the 
COVID-19 pandemic will influence the illegal drug supply (e.g., disruption of local distribution 
networks due to self-isolation) and level of contamination in the drug supply. 
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Background 
Introduction 
Use of any substance carries with it inherent risks. However, this risk is substantially increased for 
products purchased on the illegal, unregulated market as there is no quality control. It is common 
practice in the unregulated market to mix additional substances into drugs to add bulk or enhance 
the effects. It is also possible to unintentionally include contaminants as a by-product of the 
manufacturing process (Cole et al., 2011). As a result, drugs can contain unexpected substances of 
unknown quantities and have unknown potency and toxicity. This increases the risk of accidental 
poisoning and other harms as people do not know what substances they are using or how much. 
This report is intended to accompany the CCENDU Bulletin of the same name and provides much of 
the technical details and methods used to generate the results presented in the bulletin. The 
Canadian Community Epidemiology Network on Drug Use (CCENDU) is a nationwide network of 
community-level partners in 10 locations across the country who share information about local 
trends and emerging issues in substance use that they see in their own communities. CCENDU has 
reported on accidental substance poisoning trends in the past (CCENDU 2014, 2016, & 2019).  
This report provides an overview of the array of substances frequently found in drugs on the unregulated 
market in Canada, using data from multiple sources. The report aims to raise awareness that drug 
adulteration is extensive and pervasive, and contributes to drug-related harms, with a view to enabling 
more informed decision making among stakeholders, including people who use drugs (e.g., using 
harm reduction services or not using alone), direct service providers (e.g., managing unintentional 
polysubstance use among people accessing services) and policy makers (e.g., investigating options 
for creating a more predictable drug supply). 
Results are based on the best available data, but due to data collection limitations they do not 
provide a comprehensive account of all substances currently found in drugs circulating on the 
unregulated drug marketplace.  
Method 
Data sources for this report are described in detail in Appendix A. In brief, they include: 
• Health Canada’s Drug Analysis Service (DAS): A service that analyzes suspected illegal drugs 
seized by law enforcement. The data generated by DAS include all substances contained in each 
sample, but not their quantities or what the substance was intended to be bought or sold as. 
The report includes DAS data from April 2018 to August 2019. 
• Canadian Border Services Agency (CBSA): This agency also analyzes select samples seized at 
Canadian ports of entry. For this report, CBSA provided results of fentanyl, methamphetamine 
and cocaine seizures. The report includes CBSA data from 2017 to July 2019. 
• Drug Content Monitoring Study: A research pilot by the B.C. Centre for Disease Control and 
Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Ile-de-Montréal, 
comparing self-reported recent substance use to urinalysis results. Data were collected between 
May and August 2018 in B.C. and between August and September 2018 in Montreal. 
• Drug Checking Working Group (DCWG): A collection of drug checking service providers and 
researchers from across Canada. For this report, DCWG members provided information on the 
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contents of submitted samples along with information on service user expectations. The 
reporting timeframe spans 2018 and 2019. 
• Life Labs: A commercial laboratory providing urinalysis services. For this report, they provided a 
summary report of aggregated urine toxicology results indicating exposure to certain substances. 
This report uses data released in August 2019, reporting on the previous 26 weeks. 
An Important Note on Terminology  
Cole et al. (2011) describe several categories of substances that can be present in drugs in addition to the 
expected substance. These categories have important differences, but for the purpose of this report we 
collectively refer to them as adulterants. They include:  
• Adulterants: Pharmacologically active ingredients that are added to enhance or mimic the effects of the 
expected substance;  
• Diluents: Inert substances added for bulk, such as talcum powder or sugar; and 
• Contaminants: By-products of the manufacturing process and unintentionally added substances (e.g., 
cross-contamination from poorly cleaned scales). 
While people who use drugs are often aware that adulteration occurs during production or distribution of 
illegal drugs, we use the term unexpected to refer to a lack of awareness of specific adulterants and their 
concentration in a given sample. 
In describing the contents of drugs purchased on the unregulated market, terminology can be challenging as 
the most frequently used terms, adulterant or contaminant, are ambiguous unless the expectation of the 
individual using the drug is known. For clarity, we use the terms adulterant or contaminant in situations 
where expectations can be assessed (e.g., drug checking), and the term co-occurring substance when the 
expectation of the contents is unknown (e.g., DAS data).  
Further, since DAS does not report the quantity of each substance in a sample, it is unknown whether a 
given substance is the dominant ingredient or merely present in trace amounts. For this reason, it is not 
possible to use terms such as “opioid samples” or “stimulant samples” when describing the DAS data. We 
use opioid-containing samples to refer to samples that contain any amount of at least one opioid, including 
heroin, fentanyl, fentanyl analogues, non-fentanyl synthetic opioids and others, and stimulant-containing 
samples to refer to samples that contain any amount of at least one stimulant, for this report including 
methamphetamine, cocaine or MDMA. 
The term cutting agent refers to adulterants or co-occurring substances that are typically not psychoactive 
and are unlikely to contribute to accidental substance poisoning, although some may be associated with 
other health risks (Brunt, van den Berg, Pennings, & Venhuis, 2017; Carcinogenic Potency Project, 2007). 
Finally, in line with the Lexicon of Non-Stigmatizing Substance Use-Related Language developed by the 
Public Health Agency of Canada (2020), we refer to (accidental) substance poisoning rather than overdose, 
where possible, except when the latter is part of a commonly used phrase (e.g., “overdose response team”).  
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Results 
This section is a non-exhaustive sampling of the contents of drugs circulating on the unregulated 
market, illustrating how common and diverse drug adulteration is in Canada.  
The main, high-level findings are as follows:  
• Drugs bought and sold on the illegal market frequently contain unexpected psychoactive 
substances and cutting agents. 
• Fentanyl and its analogues are common in the illegal drug supply, but are not always used 
intentionally or knowingly. 
• Other psychoactive adulterants such as benzodiazepines, non-fentanyl synthetic opioids and 
synthetic cannabinoids are also present in the illegal drug supply and contribute to health risks. 
• There is significant regional variation in supply, demand and co-occurrence of substances. 
Unexpected Psychoactive Substances and Cutting Agents 
Key Finding Drugs obtained on the illegal market tend to contain unexpected substances 
Supported By DAS data  Drug content monitoring study  Drug checking  
Section Summary 
A significant number of drugs circulating on the Canadian market contain 
multiple substances. Over two-thirds of opioid-containing samples analyzed 
by DAS contained additional, non-opioid substances. Up to half of stimulant-
containing samples also contained additional substances. Many of these 
additional substances were cutting agents and there was significant regional 
variation (see section on regional variation, below). Drug checking and drug 
content monitoring (survey and urinalysis) data showed that the presence of 
multiple substances is often unexpected and creates a mismatch between 
drug contents and consumer expectations.  
Between April 2018 and August 2019, DAS analyzed 167,630 unique samples submitted 
nationwide. Of these samples: 
• 23% (n = 38,429) contained cocaine; 
• 22% (n = 37,625) contained methamphetamine; 
• 14% (n = 23,338) contained an opioid; and 
• 2% (n = 2,777) contained MDMA.  
Tables 1a and 2 present information on the composition of these samples. The tables specify the 
frequency with which additional substances appeared alongside substances of interest, with 
particular attention to opioids, benzodiazepines and synthetic cannabinoids, based on trends from 
other data sources. Table 1b details the frequency with which certain opioids of interest appeared 
among the opioid-containing samples. 
The DAS data summarized in Tables 1a and 2 indicate that: 
• Over two-thirds of opioid-containing samples (69%) contained at least one other, non-opioid 
substance. However, much of this was accounted for by cutting agents such as caffeine, 
dimethylsulfone and non-opioid pain relievers. 
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- Excluding cutting agents, 13% of opioid-containing samples contained at least one other 
psychoactive substance. 
• About half (46%) of methamphetamine-containing samples contained additional substances, 
much of this accounted for by cutting agents such as caffeine and diphenhydramine. 
- Excluding cutting agents, 11% contained additional psychoactive substances. 
• Nearly a third (29%) of cocaine-containing samples also contained additional substances, much 
of this accounted for by cutting agents such as phenacetin, local anesthetics and levamisole. 
- Excluding cutting agents, 5% contained additional psychoactive substances. 
Table 1a. Non-opioid substances in opioid-containing samples submitted to DAS  
(April 2018 – August 2019; n = 23,338) 
Co-occurring substances Appear in number (%) of samples 
None, only opioids present 7,242 (31%) 
Other psychoactive substances (any) 2,998 (13%) 
Benzodiazepines1  85 (<1%); of these, 57 (67%) etizolam 
Synthetic cannabinoids  70 (<1%) 
Other commonly detected  
psychoactive substances2 
Methamphetamine: 1,193 (5%) 
Cocaine: 1,025 (4%) 
Cutting agents3 Caffeine: 13,818 (59%) 
Dimethylsulfone: 2,963 (13%) 
Non-opioid analgesics:4 1,903 (8%); of these, 340 (18%) phenacetin 
Table 1b. Specific opioids of interest in opioid-containing samples submitted to DAS  
(April 2018 – August 2019; n = 23,338) 
Opioid of interest Appears in number (%) of samples 
Heroin 5,136 (22%) 
Fentanyl or fentanyl analogues 14,424 (62%); of these, 1,999 (14%) carfentanil 
Non-fentanyl synthetic opioids5 196 (1%); of these, 184 (94%) U-47700 
Note: The categories of co-occurring substances are not mutually exclusive and therefore do not add up to the total n. 
                                                 
1 This category also includes “z-drugs,” which are not benzodiazepines but have similar effects. 
2 Detected in more than 1% of samples. 
3 Cutting agents include acetaminophen, acetylprocaine, acetylsalicylic acid, benzocaine, caffeine, chloroprocaine, chloroquine or its salts, 
dimethylsulphone, hydroxychloroquine or its salts, levamisole, lidocaine, mannitol, phenacetin, procaine, quinine or its salts or derivatives, 
and quinidine. 
4 Non-opioid analgesics include phenacetin, acetaminophen and ibuprofen. 
5 Non-fentanyl synthetic opioids include U-47109, U-47700, U-48520, U-48800, U-49900, U-50211, U-50221, U-51754, U-77891 and 
NMU-47931E. 
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Table 2. Substances detected in stimulant-containing samples submitted to DAS  
(April 2018 – August 2019) 
 Methamphetamine  
(n = 37,625) 
Cocaine   
(n = 38,429) 
MDMA  
(n = 2,777) 
Co-occurring substances Number (%) of samples Number (%) of samples Number (%) of samples 
None – only the specific 
stimulant present 
20,285 (54%) 27,342 (71%) 2,293 (83%) 
Other psychoactive 
substances (any) 
4,246 (11%) 2,044 (5%) 415 (15%) 
Opioids (any) 1,193 (3%) 1,025 (3%) 43 (2%) 
Heroin 279 (1%) 216 (1%) 4 (<1%) 
Fentanyl or fentanyl 
analogues 
1,021 (3%) 
Of these, 165 (16%) 
carfentanil 
931 (2%) 
Of these, 116 (12%) 
carfentanil 
33 (1%) 









Benzodiazepines 41 (<1%) 
Of these, 17 (41%) 
etizolam 
25 (<1%) 
Of these, 3 (12%) etizolam 
2 (<1%) 
None etizolam 
Synthetic cannabinoids 5 (<1%) 3 (<1%) 1 (<1%) 




Cocaine: 891 (2%) 
Methamphetamine: 891 
(2%) 
Methamphetamine: 119 (4%) 
Diphenhydramine: 107 (4%) 
Cocaine: 53 (2%) 
MDA: 52 (2%) 
Benzylpiperazine (BZP): 34 
(1%) 
Ketamine: 32 (1%) 
Cutting agents Caffeine: 16,166 (43%) Non-opioid analgesics: 
4,819 (13%); of these, 
4,664 (97%) phenacetin 
Local anesthetics:6 4,074 
(11%) 
Caffeine: 2,824 (7%) 
Levamisole: 1,095 (3%) 
Caffeine: 164 (6%) 
Non-opioid analgesics: 36 
(1%); of these, 35 (97%) 
phenacetin 
Local anesthetics: 35 (1%) 
Dimethylsulphone: 33 (1%) 
Note: The categories of co-occurring substances are not mutually exclusive and therefore do not add up to the total n. 
Among samples seized at Canada’s borders (CBSA data), a similar pattern of co-occurrence emerged: 
• Among fentanyl samples, 36% (n = 60/166) included another substance (15 of these [25%] 
were carfentanil).  
• Among cocaine samples, 83% (n = 302/364) included another substance. In 69% of these 
cases (n = 207/302) the other substance was levamisole. Other cutting agents included 
phenacetin and caffeine.  
• Among methamphetamine samples, 21% (n = 67/324) included another substance, primarily 
cutting agents such as caffeine and dimethylsulphone. 
                                                 
6 Local anesthetics include procaine, lidocaine and benzocaine. 
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Drug checking data further confirmed frequent discrepancies between the expectations of people 
using drug checking services and the contents of their drugs. The discrepancies include unexpected 
additional substances (as reflected in the DAS and CBSA data), as well as drug substitutions or 
instances where the expected substance was absent.  
• Drug checking services in Toronto found that between July and October 2019, 43% of all 
submitted samples (n = 101/233) contained at least one unexpected noteworthy drug.7 
• These services also found that only 6% of samples expected to be an opioid (n = 97), 34% of 
samples expected to be a stimulant (n = 47), and 72% of samples expected to be a psychedelic 
(n = 71) contained mostly (greater or equal to 75%) the expected substance relative to other 
substances in the sample (not including non-drug fillers). 
• Among samples analysed by B.C. drug checking services between January and July 2019, 11% 
of samples expected to be opioids (n = 228/2,127), 2% of stimulants (n = 10/571), 23% of 
depressants (n = 22/94), and 9% of psychedelics (45/518) did not match client expectations. 
• At a 2018 festival in B.C., 11% of samples submitted as MDMA and 8% of samples submitted as 
cocaine did not include the expected drug. 
• In Quebec, colorimetric testing at a music festival by Projet Cameleon, for which service users 
primarily tested MDMA, cocaine, and ketamine, found that 44% of samples analyzed met client 
expectations and 41% did not. 
Finally, survey and urinalysis data from the drug content monitoring study supported the drug 
checking findings, confirming exposure to substances other than those intended by showing 
discrepancies between reported drug use and substances appearing in urinalysis.  
• In B.C., up to 36% of respondents had positive urine screens for substances they did not report 
using, suggesting unexpected exposure. Up to 26% had negative urine screens for substances 
they did report using, meaning they consumed unexpected or inert substances instead. 
• In Montreal, findings confirmed adulteration of cocaine with levamisole and local anesthetics, as 
observed by DAS and CBSA. The most frequent substances people assumed they had consumed 
in the past three days were crack, cocaine, and speed; the most commonly detected substances 
in urinalysis were cocaine, levamisole, methamphetamine, and lidocaine. Levamisole and 
lidocaine detection were associated with reported crack or cocaine use. 
Fentanyl and Its Analogues in the Illegal Drug Supply 
Key Finding Fentanyl and its analogues are common in the illegal drug supply 
Supported By DAS data  Drug content monitoring study  Drug checking  
Section Summary 
DAS data identified fentanyl or its analogues in nearly two-thirds (62%) of 
opioid-containing and up to 3% of stimulant-containing samples nationwide. 
Fentanyl presence was particularly high in B.C., where fentanyl or analogues 
were present in 91% of opioid-containing samples and up to 10% of 
stimulant-containing samples (see regional variation section for more detail). 
                                                 
7 A noteworthy drug is defined by the Centre on Drug Policy Evaluation as highly potent, linked to overdose or other adverse effects, or a 
drug that might not be desired by some clients. 
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The DAS data in Tables 1a, 1b and 2, along with CBSA and Life Labs urine toxicology data, give some 
indication of the frequency with which fentanyl and its analogues appear in the drug supply.  
• Nationally, nearly two-thirds (62%) of opioid-containing samples analyzed by DAS included 
fentanyl or its analogues. Carfentanil was the analogue in 14% of these cases.  
- CBSA data showed similar results. Among seized fentanyl samples, 9% (n = 15/166) also 
contained carfentanil. 
- Data provided by Life Labs in B.C. indicated that among fentanyl-positive urine samples, up 
to 13.9% also screened positive for carfentanil between February and May 2019.  
• Although fentanyl and analogues were most likely to co-occur with other opioids, they co-
occurred with stimulants (most often methamphetamine) in up to 3% of cases, in line with 
previous CCENDU reports (2019).  
• In B.C., the presence of fentanyl or its analogues climbed to 91% among opioid-containing 
samples and up to 10% among stimulant-containing samples (see regional variation section). 
Key Finding Fentanyl and its analogues are not always used intentionally or knowingly 
Supported By DAS data  Drug content monitoring study  Drug checking  
Section Summary 
The presence of fentanyl and analogues in the drug supply does not 
necessarily reflect demand; some of it reflects adulteration. Drug content 
monitoring (survey and urinalysis) and drug checking data showed that their 
presence was not always expected: While some survey respondents reported 
intentionally or knowingly using fentanyl, over one-third (36%) of B.C. 
respondents with fentanyl-positive urine and over 90% of Montreal 
respondents with fentanyl-positive urine, did not report using fentanyl; that is, 
they were unintentionally or unknowingly exposed. Drug checking further 
revealed fentanyl in drugs thought to be heroin, stimulants and 
pharmaceuticals. It also revealed unexpected carfentanil and other 
analogues in drugs thought to be fentanyl.  
Survey and urinalysis data from the drug content monitoring study revealed fentanyl in the urine of 
people who did not report using it and this lack of awareness can contribute to overdose deaths. 
• In B.C., among individuals whose urine tested positive for fentanyl (n = 183/309), only 64% 
reported using it in the past three days, suggesting over one-third (36%) were unintentionally or 
unknowingly exposed.  
• In Montreal, among the 33 out of 341 individuals whose urine tested positive for fentanyl and 
analogues, only three reported using it, suggesting over 90% were unintentionally or 
unknowingly exposed. 
• In addition, the presence of carfentanil in urine analyzed by Life Labs in Ontario was detected 
frequently enough that they deemed it necessary to alert public health authorities. In June 
2019, Toronto Public Health released a bulletin on increased carfentanil presence with 
information provided by the provincial Ministry of Health, which included data from the Chief 
Coroner for Ontario, showing 142 carfentanil-related deaths in the first four months of 2019 
alone, a 50% increase from carfentanil-related deaths in all of 2018 (95 deaths) (Toronto Public 
Health, 2019a).  
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Drug checking reports, in line with the survey and urinalysis data, further showed that not all fentanyl 
is used intentionally or knowingly. Though there was considerable variability in the nature of the 
reports, all sites reported unexpected fentanyl or analogues in analyzed samples (see Table 3). 
Among drug checking services in B.C.:  
• 70% of samples submitted as opioids between January and July 2019 were expected to contain 
fentanyl, yet 88% tested positive for fentanyl, in some cases prompting public health 
notifications (e.g., fentanyl in counterfeit Percocet™) (Government of B.C., 2019). 
• A pilot study conducted in August 2019 confirmed that most samples submitted as “down” 
contained fentanyl (75%, n = 45/60). The study also consistently detected 4-ANPP, the 
carcinogenic precursor to fentanyl, suggesting illegal manufacture.  
• Fentanyl was also detected in 1% of samples expected to be stimulants (n = 5/571) and 1% of 
samples expected to be depressants (n = 5/94), prompting further public health notifications 
(e.g., cocaine containing opioids and in some cases no cocaine, or counterfeit Xanax™ 
(alprazolam) containing fentanyl or synthetic cannabinoids and in some cases no alprazolam 
(Government of B.C., 2019). 
In Ontario, samples submitted to Oasis as speed or crystal meth between September and December 
2018 contained methamphetamine in combination with fentanyl and fentanyl analogues, non-
fentanyl synthetic opioids, non-opioid adulterants and cutting agents (see Table 3).  
However, detection of fentanyl in stimulants was not consistent across sources.  
• Fentanyl immunoassay strips used by ANKORS at a music festival in B.C. showed that of 1,971 
samples tested in 2017, 35 samples (1.8%) — primarily thought to be ketamine, MDMA, cocaine 
or hallucinogens — tested positive for fentanyl. However, at the same festival in 2018, fentanyl 
strips identified one fentanyl-positive sample of 2,410, and in 2019, 0 of 3,485.  
• Consistent with this observation, the August 2019 pilot study in B.C. found no fentanyl in 
samples submitted as “side, speed, or Crystal,” expected to contain methamphetamine as the 
primary constituent (n = 29). At the same time, four of these samples also did not contain 
methamphetamine as the primary constituent. 
Other Psychoactive Adulterants Associated with Health Harms 
Key Finding Increasingly, reports also point to unexpected benzodiazepines, non-fentanyl synthetic opioids and synthetic cannabinoids as contributing to health risks 
Supported By DAS data  Drug content monitoring study  Drug checking  
Section Summary 
Drug checking consistently found novel synthetic opioids (especially U-47700 
and other U-Series compounds), benzodiazepines (especially etizolam, 
flualprazolam and flubromazolam) and synthetic cannabinoids (especially 
AMB-FUBINACA). DAS and urine toxicology data confirmed their presence in 
the drug supply, most often in combination with opioids. These substances 
are of concern because they are not always detected by test strips and can 
alter the response to overdose interventions. 
In addition to opioids, other psychoactive adulterants such as benzodiazepines, non-fentanyl 
synthetic opioids and synthetic cannabinoids are also present in the illegal drug supply and can 
contribute to health risks. Table 3 shows that drug checking identified a wide variety of adulterants 
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in samples submitted for analysis. Three categories of substances linked to health risks were 
consistently reported: non-fentanyl synthetic opioids, benzodiazepines and synthetic cannabinoids.  
• In an August 2019 pilot study in B.C., of 15 “down” samples that did not contain fentanyl, nine 
tested positive for etizolam. Three of the samples contained both etizolam and fentanyl.  
• In Ontario, among samples submitted to Oasis as “down,” heroin, or fentanyl between 
September and December 2018 (n = 56), seven contained fentanyl only; the rest were found to 
contain various combinations of fentanyl analogues, non-fentanyl synthetic opioids and cutting 
agents (see Table 3).  
• In January 2019, a Toronto Public Health bulletin reported that some drugs sold as fentanyl or 
heroin in Ontario were causing severe anxiety, memory lapses, erratic behaviour, hallucinations, 
rapid heart rate and shortness of breath. Analysis of residue from used injection equipment 
revealed that a synthetic cannabinoid, AMB-FUBINACA, was a major component in addition to 
fentanyl and heroin (Toronto Public Health, 2019b). Other compounds in the residue included an 
array of fentanyl analogues, non-opioid adulterants and cutting agents (see Table 3).  
DAS, CBSA and urine toxicology data confirmed the presence of these substances in the drug supply. 
• Among DAS data, benzodiazepines and synthetic cannabinoids co-occurred with opioids more 
often than with stimulants (see Tables 1a and 2).  
• CBSA noted the appearance of novel synthetic opioids commonly considered adulterants, 
including U-47700, U-48800 and U-49900, in samples submitted for analysis. 
• Life Labs data from B.C. showed increasing etizolam presence among benzodiazepine-positive 
urine samples between July 2018 and August 2019, as well as flubromazolam presence in 5–
10% of all urine samples.  
• Life Labs data also indicated that over the course of 2019, among fentanyl-positive urine 
samples, up to 10% also screened positive for U-47700.  
Table 3. Notable findings from Canadian drug checking services8  
 B.C. Ontario Quebec9 
Substances 
identified in 





• Synthetic cannabinoids 
(AMB-FUBINACA) 
• Etizolam,  
• Flubromazolam 
• Dextromethorphan 
• Common cutting agents: 
caffeine, sweeteners, 
vitamin C, polyethylene 
glycol, noscapine, xylazine 
• Plaster 
Oasis: 
• Fentanyl, acetylfentanyl, 
acrylfentanyl, carfentanil, 
furanylfentanyl 







Ontario Harm Reduction Network: 
• AMB-FUBINACA 
• Etizolam  
• Acetylfentanyl, butyrfentanyl  
• Codeine 
• Fentanyl 
                                                 
8 For details on individual drug checking services, see Appendix A. 
9 The difference in notable results between Quebec and other provinces reflects a difference in available drug checking equipment and 
not necessarily a difference in adulterants or rates of adulteration. 
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 B.C. Ontario Quebec9 
• Ketamine 
• Methamphetamine 
• Cocaine, benzocaine 
• MDMA 
• Cutting agents: Caffeine, 
phenacetin, acetaminophen 
Centre on Drug Policy Evaluation: 
• Fentanyl, 4‐ANPP 
• Heroin, 6‐MAM 
• Morphine  
• Codeine, acetylcodeine 
• Benzodiazepine 
• Cocaine 








• Methamphetamine in 
cocaine 















Oasis (expected cocaine): 
• Fentanyl, furanylfentanyl 





• Caffeine, phenacetin 
Centre on Drug Policy Evaluation: 
• Cocaine 






• Methamphetamine in 
cocaine 
Substances 
identified in other 
drugs  
Found in depressants 
(including counterfeit Xanax™): 
• Fentanyl 
• U-47700  
• 5F-ADB 
• AMB-FUBINACA 
• Caffeine  
All samples combined: 
• Phenacetin 
• Carfentanil 
• Etizolam  
• Levamisole  
• AMB‐FUBINACA 
• Flubromazolam 
• Flualprazolam  
No data available 
Note: Because drug checking reporting conventions vary, entries could not be ordered by frequency. 
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Regional Variation in Availability and Co-occurrence of Substances 
Key Finding There is significant regional variation in supply, demand and co-occurrence of substances 
Supported By DAS data  Drug content monitoring study  Drug checking  
Section Summary 
According to the data in this report, there is more fentanyl in the unregulated 
drug supply in western Canada than in the east. Further, opioids are more 
often contaminated with other substances in the west than in the east. 
Stimulant supply and demand are high across the country, but in the east, 
stimulant availability is significantly higher than that for opioids and 
stimulants are more often contaminated with other substances than in the 
west. However, even though DAS detected more substances co-occurring 
with methamphetamine in the east than in the west, these were mostly 
cutting agents; in the west they included fentanyl and its analogues.  
There Is More Fentanyl in Western Canada 
Among opioid-containing samples analyzed by DAS, the west had the highest presence of fentanyl, 
its analogues and other, non-opioid substances, whereas the east had the lowest presence of each. 
• In B.C., fentanyl and analogues were detected in 91% of opioid-containing samples 
(n = 5,873/6,475), compared to 62% nationally.  
• Comparatively, among opioid-containing samples from the four Atlantic provinces and Quebec, 
only 8% (n = 55/723) and 14%, (n = 254/1,857), respectively, included fentanyl or its analogues.  
These results are consistent with survey data from the drug content monitoring study.  
• In B.C., fentanyl was the third-most frequently reported substance consumed in the past three 
days (reported by 43% of respondents) and the second-most detected in urine (detected in 59% 
of respondents).  
• In contrast, fentanyl was not among the top five most frequently reported or detected 
substances among Montreal respondents. 
There Are More Substances Co-occurring with Opioids in Western Canada 
• In B.C., 91% of opioid-containing samples (n = 5,885/6,475) analyzed by DAS also included 
other, non-opioid substances (including cutting agents), compared 69% nationally. Excluding 
cutting agents, 15% (n = 985/6,475) included other, non-opioid substances; this concentration 
was still the highest in the country. 
• In contrast, 25% of opioid-containing samples from Quebec (n = 465/1,869) included other, 
non-opioid substances (7%, n = 132/1,869 without cutting agents). 
Stimulants Dominate the Unregulated Drug Market in Eastern Canada 
Among stimulant-containing samples analyzed by DAS:  
• The greatest number of methamphetamine-containing samples were from Quebec 
(n = 14,269/37,625 or 38% of all methamphetamine-containing samples seized nationwide). 
• The greatest number of cocaine-containing samples were from Ontario (n = 14,329/38,429 or 
37% of all cocaine-containing samples nationwide) and Quebec (n = 10,266/38,429 or 27%). 
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• The DAS data are consistent with survey data from the drug content monitoring study in 
Montreal, where the top three most frequently reported substances were stimulants: crack 
(62%), cocaine (41%) and speed/amphetamine (25%).  
Among Stimulant-containing Samples, Co-occurring Substances Are More Common in 
Eastern Canada, but Pose Greater Risk in Western Canada  
• In Quebec, 95% of methamphetamine-containing samples analyzed by DAS (n = 13,489/14,269) 
included another substance, compared to 46% nationally. However, almost all of this amount 
was accounted for by caffeine and diphenhydramine (an antihistamine), appearing in 93.5% and 
12.5% of samples respectively.10 
• In contrast, few methamphetamine-containing samples included other substances in the 
Prairies and western Canada. In Saskatchewan, co-occurring substances were identified in only 
3% of methamphetamine-containing samples (n = 24/758); in Alberta 5% (n = 331/6,518); in 
Manitoba 14% (n = 151/1,060); and in B.C. 13% (n = 598/4,783). 
However, although overall co-occurrence of additional substances in stimulant-containing samples 
was low in the west, presence of fentanyl and its analogues among these co-occurring substances 
was highest in B.C. 
• In B.C., fentanyl or its analogues were present in 10% of methamphetamine-containing samples 
(n = 467/4,783) and 7% of cocaine-containing samples (n = 389/5,274). Nationally this 
proportion was 3% and in Quebec less than 1%.  
                                                 
10 Note that categories are not mutually exclusive and therefore do not add up to 100%. 
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Conclusions and Implications 
These data demonstrate that the Canadian illegal drug supply is unpredictable. As a result, people 
who use drugs often do not know what or how much they are consuming, and are accordingly unable 
to manage their risks. While no drug is risk-free, this unpredictability can dramatically increase the 
negative health consequences of drug use, especially accidental substance poisoning. 
Unexpected Psychoactive Substances and Cutting Agents 
Fentanyl and Fentanyl Analogues 
Chief among the substances of concern are fentanyl and fentanyl analogues, particularly carfentanil. 
Carfentanil is stronger and more toxic than fentanyl (Stewart, 2017) and has been linked to a recent 
spike in overdose deaths. Although many people in some parts of the country have come to 
intentionally seek out fentanyl or are at least aware that it is likely present, urinalysis and drug 
checking data indicate that not everyone who uses fentanyl does so intentionally or knowingly. 
Further, those who do seek fentanyl might be exposed to a more toxic analogue instead. When 
people do not know what substances they are using or how much, they are at increased risk of 
accidental poisoning and other harms. This possibility is especially true for people who are not 
expecting to consume opioids. For example, people expecting to use a stimulant might be opioid 
naïve or have a low opioid tolerance, and might not be prepared with opioid harm reduction 
measures (e.g., carrying naloxone). 
Benzodiazepines, Synthetic Cannabinoids and Other Opioids 
Drug checking and urinalysis sources frequently flagged the appearance of unexpected 
benzodiazepines, synthetic cannabinoids and non-fentanyl synthetic opioids, particularly in 
combination with other opioids. This finding raises two concerns: 
1. These substances are not always detected by drug checking technologies, such as immunoassay 
test strips, which might mean that individuals who have their drugs checked might misinterpret 
their results as indicating that their drugs have not been adulterated.   
2. The presence of benzodiazepines, synthetic cannabinoids and non-fentanyl synthetic opioids can 
result in medical emergencies that present with less typical and more complex symptoms and do 
not always respond as expected to naloxone. For example, because benzodiazepines are 
depressants, they can intensify opioid effects like slowed breathing, but benzodiazepine effects 
can not be reversed by naloxone.  
Cutting Agents 
Based on the data sources available, up to 91% of drugs can contain adulterants. The majority of 
these are cutting agents, whose presence poses two main health risks: 
1. The presence and quantity vary from one batch of drugs to another and can influence the 
concentration of the expected psychoactive substance in the drug, making it unpredictable. 
2. Some have been associated with negative health consequences themselves. For example, 
levamisole, which consistently appears in cocaine, has been linked to blood and vascular 
pathologies causing tissue necrosis (Brunt et al., 2017); phenacetin, which was found in opioids 
and stimulants, has been linked to cancer and kidney disease (Carcinogenic Potency Project, 
2007); and added detergent burned the throats of people who inadvertently smoked it. This 
suggests that cutting agents contribute to the health risks created by an unpredictable supply. 
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Regional Variation in Supply, Demand and Substance Co-occurrence 
Another noteworthy finding is that drug supply and substance co-occurrence patterns differed greatly 
between eastern and western Canada. There appears to be more fentanyl in western Canada than in 
the east, while stimulants dominate the illegal drug market in eastern Canada. Substance co-
occurrence patterns also differed by region, affecting the opioid supply more in the west and the 
stimulant supply more in the east. However, in B.C., fentanyl presence was the highest in both 
opioids and stimulants, suggesting adulteration across the supply in this province.  
While it is suspected that some of these differences stem from different supply routes and distribution 
networks across the country (e.g., the vast majority of fentanyl is thought to originate in China, 
making B.C. the nearest port of entry), more research is needed to determine the reasons for this 
regional variation. 
Implications and Next Steps 
Based on the findings from this report, the following actions could be considered going forward. 
Investing in the collection and dissemination of better quality and more timely data on substances in 
the unregulated drug supply in Canada should be a priority. This investment could be made through 
developing a Canadian drug observatory service, which would: 
• Monitor the contents of the drug supply over time to detect the appearance of, or changes in, 
adulterants and contaminants, track any adverse health effects, and share these results in a 
timely fashion; 
• Work with drug checking programs to standardize drug checking data so that it can better 
inform drug market monitoring efforts and allow for regional comparability; 
• Centralize public health alerts into a publicly accessible database so that jurisdictions can 
readily access and share information; and 
• Raise public awareness of the link between lack of quality control in the unregulated drug 
market and health risks, particularly accidental substance poisoning. 
The capacity of harm reduction services could be developed, and access to them improved, including: 
• Investing in dissemination of targeted, fact-based, and non-judgmental information to ensure that 
people who use drugs are aware of potential contaminants, ways to reduce risks (e.g., using 
harm reduction services, not using alone), and ways to identify and intervene in an overdose.  
• Supporting the development and sustainability of low-barrier, easily accessible harm reduction 
services such as drug checking and supervised consumption services, and expanding them to 
different regions across the country, to provide a national picture and tailor responses to each 
region’s particular drug use and adulteration patterns;  
• Continuing to encourage first responders and others to carry naloxone and be trained on 
appropriate overdose response protocols, including updated protocols focused on inadvertent 
use of multiple substances; and 
• Increasing investment in a range of treatment options to ensure that people who use drugs and 
those with a substance use disorder receive the needed services. 
Approaches that can decrease drug-related harms by increasing the predictability of drug contents 
should be advanced. Such approaches include “safer supply” programs such as injectable opioid 
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agonist treatment (e.g., hydromorphone or diacetylmorphine) (Fairbairn et al., 2019) and low-barrier 
opioid distribution programs (Tyndall, 2018). As the evidence around some of these approaches is 
limited, next steps could include: 
• Synthesizing the available evidence to identify research gaps and formulating recommendations 
to address them; 
• Exploring and evaluating various models of delivery of such interventions to produce evidence-
informed recommendations for program development, scale-up and sustainability; 
• Evaluating context variables to assess what works best, for whom and why, as well as evaluating 
the long-term safety and efficacy of these interventions; 
• Investigating the feasibility of applying a similar approach to non-opioid drugs, in light of our 
finding that contamination is widespread across the drug supply and that there is increased 
methamphetamine use across the country. Proposals for stimulant substitution or distribution 
programs have been put forward (Canadian Association of People Who Use Drugs, 2019; 
Fleming, Barker, Ivsins, Vakharia, & McNeil, 2020) and could be piloted and evaluated; and 
• Analyzing the regulatory and policy barriers that need to be addressed, and employing the policy 
levers and facilitators that are available, to enable the development, scale-up and stability of 
successful interventions beyond the pilot phase. 
It will also be important to monitor and assess whether large scale social changes resulting from the 
COVID-19 pandemic will influence the illegal drug supply (e.g., disruption of local distribution 
networks due to self-isolation) and level of contamination in the drug supply. 
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Appendix A: Data Sources 
Source Details Limitations Time Frame 






In April 2018, Health Canada’s DAS 
laboratory began sharing with partners 
the results of analyses of seized 
controlled drugs. The database lists all 
substances contained in each sample 
submitted for analysis, providing an 
assessment of drug constituents by 
region. 
The database does not include 
information on:  
1. Quantities of each substance; 
2. Which substances were expected by 
the buyer or seller;  
3. Where in each province the sample 
was seized; or 
4. Under what circumstances samples 
were seized (e.g., small amounts 
from individuals vs. large amounts).  
The database is limited to samples 
submitted for analysis and so might not 
be representative of all substances seized 












CBSA analyzes the contents of select 
samples seized at Canadian ports of 
entry. CBSA provided results of fentanyl, 
methamphetamine and cocaine seizures. 
Though these samples provide a useful 
snapshot of the constituents of controlled 
substances seized at Canadian ports of 
entry, they do not represent the full drug 
import and export picture as not all 
suspected drugs detained at the border 




from 2017 to 
July 2019 






The DCWG is a collection of drug checking 
service providers, researchers and policy 
makers from across the country. Drug 
checking services provide information on 
the contents of samples along with 
information on service users’ expectations. 
DCWG members from British Columbia,12 
Ontario13 and Quebec14 provided 
information for this bulletin. 
Services use a variety of technologies and 
protocols for collecting and reporting data 
(see Centre on Drug Policy Evaluation, 
2018; Kerr & Tupper, 2017, for further 
detail on limitations of each). 
Reporting 
timeframes 
vary, but span 
2018 and 
2019, as 
noted in the 
text 
                                                 
11 Results presented here are based on monthly raw data shared by DAS. However, for ease of reporting in this bulletin, substances are 
classified differently from DAS reports, in which the system of reporting is based on the Controlled Drugs and Substances Act drug 
schedules and items. 
12 Drug checking in B.C. is supported by a partnership between the B.C. Centre on Substance Use and regional health authorities (Vancouver 
Coastal Health, Interior Health and Fraser Health), offering Fourier-transform infrared spectrometry (FTIR) and fentanyl immunoassay strips 
at supervised consumption and overdose prevention sites, music festivals and pop-up events. Drug checking results are entered into a 
common database and reports are released monthly. Public health notifications (e.g., via the Real-time Drug Alert and Response [RADAR] 
network) are additionally released as needed. The AIDS Network Kootenay Outreach and Support Society (ANKORS) further provides drug 
checking services at music festivals. A pilot trial of paper-spray mass spectrometry (PS-MS) was added to services at a harm reduction site 
in Vancouver in August 2019, providing clients with rapid identification and quantification of substances onsite. This pilot test was part of 
the Health Canada Drug Checking Technology Challenge. 
13 The Centre on Drug Policy Evaluation is leading a multi-site drug checking services pilot project in Toronto in partnership with three 
frontline harm reduction agencies and two clinical laboratories using gas chromatography and liquid chromatography-mass spectrometry 
(GC-MS, LC-MS). In addition, the Ontario Harm Reduction Network releases bulletins on issues of concern to harm reduction workers and 
people who use drugs. The Sandy Hill Community Health Centre’s Oasis Program in Ottawa provides drug checking services using mass 
spectrometry to clients of its supervised injection site. 
14 There are currently no organizations in Quebec that operate a drug checking device. In Montreal, fentanyl immunoassay strips are used 
at the four supervised consumption sites in Montreal and distributed by 14 community-based harm reduction organizations and three 
organizations in the health network (provided by Direction régionale de santé publique de Montréal). Élixir, a community organization 
based in Sherbrooke, also provides colorimetric drug checking at music festivals and events. 
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Source Details Limitations Time Frame 






Research teams in B.C. (B.C. Centre for 
Disease Control) and Montreal (Centre 
intégré universitaire de santé et de 
services sociaux du Centre-Sud-de-l’Ile-de-
Montréal) recently completed a pilot project 
with clients accessing harm reduction 
services. They were able to compare survey 
responses indicating which substances 
clients think they took to urinalysis results 
revealing what they actually took.  
The B.C. pilot included data from 486 
clients from 27 harm reduction sites, 309 
of whom provided urine samples for 
analysis. Urine toxicology was performed 
by Life Labs.  
The Montreal pilot collected surveys and 
urine of 341 people in partnership with 
10 community and institutional partners. 
Urine toxicology was performed by the 
toxicology centre of the Institut national 
de santé publique du Québec. 
The studies use convenience samples 
and rely on self-reported behaviours. 
Reported drug use on the survey covers 
the past three days, but some substances 
disappear from urine faster than that, 











Life Labs Life Labs is a commercial laboratory that 
operates in B.C. and Ontario, performing 
urine toxicology to indicate recent exposure 
to specific substances. Life Labs provided 
additional aggregated data from clients 
who contract with them (e.g., outpatient 
clinics). 
Unless linked to survey data, it is not 
possible to determine what substances 
were intended to be used or whether 
detected substances co-occurred or were 
taken separately. 
This bulletin 
uses data 
released in 
August 2019, 
reporting on 
the previous 
26 weeks 
 
